Eledon Pharmaceuticals, Inc.Eledon Pharmaceuticals, Inc.Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc.

No trades
See on Supercharts
Market capitalization
‪40.89 M‬USD
−1.90USD
‪−40.33 M‬USD
‪22.85 M‬
Beta (1Y)
−0.99

About Eledon Pharmaceuticals, Inc.

CEO
David-Alexandre C. Gros
Headquarters
Irvine
Website
Employees (FY)
20
Founded
2004
ISIN
US28617K1016
FIGI
BBG00241S542
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. Eledon Pharmaceuticals was founded on March 26, 2004 and is headquartered in Irvine, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of ELDN is 1.64 USD — it has decreased by 2.96% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Eledon Pharmaceuticals, Inc. stocks are traded under the ticker ELDN.
Eledon Pharmaceuticals, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Eledon Pharmaceuticals, Inc. has a max estimate of 39.00 USD and a min estimate of 7.00 USD.
ELDN earnings for the last quarter are −0.35 USD whereas the estimation was −0.46 USD which accounts for 23.99% surprise. Estimated earnings for the next quarter are −0.36 USD. See more details about Eledon Pharmaceuticals, Inc. earnings.
Yes, you can track Eledon Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, ELDN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Eledon Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
ELDN reached its all-time high on Sep 17, 2014 with the price of 4 864.87 USD, and its all-time low was 1.07 USD and was reached on Nov 9, 2023.
See other stocks reaching their highest and lowest prices.
As of Apr 16, 2024, the company has 20.00 employees. See our rating of the largest employees — is Eledon Pharmaceuticals, Inc. on this list?